IgG4-TREAT
Financiado
Systematic study of IgG4-autoimmune diseases to develop new treatment strategies
IgG4-autoimmune diseases (IgG4-AID) are rare but collectively correspond to a significant group of devastating diseases affectingmany different organs, e.g. skin, brain, nerves and kidney in patients that often remain unresponsive...
IgG4-autoimmune diseases (IgG4-AID) are rare but collectively correspond to a significant group of devastating diseases affectingmany different organs, e.g. skin, brain, nerves and kidney in patients that often remain unresponsive to current treatments. IgG4-AIDhave commonalities indicating a shared underlying immunopathogenesis that make a joint approach to identify new therapeutictargets and test new treatment strategies feasible and necessary. We hypothesize that genetic risk factors and a dysregulatedimmune response may lead to an increased susceptibility to produce antibodies targeting self-proteins. These are of a specialsubclass called IgG4, which are usually harmless but can cause disease in these patients by interfering with normal functions in thebody. We are the first consortium that aims to study IgG4-AID comparatively, including pathogenic IgG4, and the cells, molecules andmechanisms involved in IgG4 autoantibody production, using an explorative multi-omics approaches in combination with state-ofthe-art cell and molecular biology methodology. We will establish a new humanized mouse model of IgG4-AID for the developmentand testing of a novel immune-apheresis based therapy aimed as immediate relief therapy for all IgG4-AID patients. Our innovativetraining program combines university-based and multidisciplinary research-based training with state-of the art web-based trainingand in-person trainings by the academic and non-academic sector. We aim to foster a new generation of experts in IgG4-AID that are1) are highly employable both in the academic and industry sectors and qualified for innovative multidisciplinary translationalresearch with a focus on biomedical product development and 2) equipped with the skillsets for digitalization, awareness for genderequality and diversity and competent in sustainable research and innovation approaches to address current and future challenges,such as climate change, social inequalities and pandemics.
ver más
Duración del proyecto: 47 meses
Fecha Inicio: 2023-09-01
Fecha Fin: 2027-08-31
Fecha Fin: 2027-08-31
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-09-01
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
HORIZON-MSCA-2022-DN-01-01:
MSCA Doctoral Networks 2022
Cerrada
hace 2 años
Líder del proyecto
MEDIZINISCHE UNIVERSITAET WIEN
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5